Poseida Therapeutics Inc (PSTX)

[jondoeuk]

The company has entered into a research collaboration and exclusive license agreement with Takeda Pharma. Under the terms of the agreement, the parties will collaborate to initially develop up to six in vivo gene therapy programs utilising Poseida's tech platforms, including piggyBac, Cas-CLOVER and biodegradable nanoparticles, as well as certain emerging technologies. Takeda also has an option to add two additional programs and is obligated to provide funding for all R&D costs. Poseida will receive an upfront payment of $45M and preclinical milestones, potentially exceeding $125M. They are also eligible to receive future milestone payments of up to $2.7B for all six programs, and up to $3.6B related to additional two optional programs.